REFERENCES
- Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–9.
- Zabay JM, De La Concha EG, Ludena C, et al. B-cell hyperactivity and abnormalities in T-cell markers and immunoregulatory function in a patient with nucleoside phos-phorylase deficiency. Clin Exp Immunol 1982; 50: 610–6.
- Giblett E, Amman A, Sandman R, Wara D, Diamond L. Nucleoside phosphorylase deficiency in a child with severely defective T cell immunity and normal B cell immunity. Lancett 1975; 1: 1010.
- Ambrogi F, Petrini M, Carulli G, et al. Adenosine deam-inase activity in human cord blood lymphocyte subpopulations. Cell Immunology 1982; 73: 404–9.
- Goldschmidt-Clermont P, Petrini M, Khansari N, Fudenderg HH. The role of PNP in autologous rosette form-ing cells. Cell Immunology 1984; 87: 340–7.
- Tallman MS, Hakimian D. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995; 86: 2463–74.
- Travis LB, Curtis RE, Glimelius B, et al. Second cancer among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 1993; 85: 1932–7.
- Anderson TC, Jones SE, Soehnlen BJ, Moon TE, Griffith K, Stanley P. Immunocompetence and malignant lym-phoma: immunologic status before therapy. Cancer 1981; 48: 2072–9.
- Ambrogi F, Polidori R, Azzara A, Petrini M, Grassi B. Leucocyte migration inhibitory activity in the serum of patients affected by Hodgkin's disease and other Iimmunoproliferative diseases. Eur J Cancer 1978; 14: 1107–12.
- Travis LB, Curtis RE, Boice Jr JD, Hankey BF, FraumeniJrJF. Second cancers following non-Hodgkin's lym-phoma. Cancer 1991; 67: 2002–9.
- MacDougall B, Weinerman BH, Kemel S. Second malignancies in non-Hodgkin's lymphoma. Cancer 1981; 48: 1299–301.
- Hemminki K, Jiang Y, Steieck G. Skin cancer and non-Hodgkin's lymphoma as second malignancies: markers of impaired immune function? Eur J Cancer 2003; 39: 223–9.